Amarin Entered into an Exclusive Agreement with Lotus Pharmaceuticals to Commercialize Vazkepa (icosapent ethyl) in Southeast Asia and South Korea
Shots:
- Amarin will receive an up front, pricing, and reimbursement & sales milestones based on net sales of the product & will be responsible for supplying the finished product to Lotus at a pre-defined supply price
- Lotus to get an exclusive right to distribution and commercial promotion for Vazkepa in South Korea and 9 countries in ASEAN: Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam
- The collaboration uses Lotus’ commercial and marketing expertise to bring novel and transformative treatments to patients & broadens the reach of Vazkepa to additional ten countries. Vazkepa capsules were approved & commercialized in a no. of global markets, incl. the US & EU markets
Ref: Amarin | Image: Amarin
Related News:- Amarin Reports (REDUCE-IT) Study Results of Vascepa/Vazkepa (icosapent ethyl) for Acute Coronary Syndrome Event
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
